Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer
Authors:
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 158, 104920
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG-17672)
- Louis Stokes Alliances for Minority Participation (LSAMP) Program
This publication has 57 references indexed in Scilit:
- Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and MetastasisClinical Cancer Research, 2012
- Anaplastic thyroid carcinoma: palliation or treatment?Current Opinion in Otolaryngology & Head and Neck Surgery, 2011
- Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptorLeukemia, 2008
- Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancerEndocrine-Related Cancer, 2008
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor ActivityCancer Research, 2008
- Molecular basis for sunitinib efficacy and future clinical developmentNature Reviews Drug Discovery, 2007
- Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude miceMolecular Cancer Therapeutics, 2007
- Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activityBlood, 2005
- Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibBlood, 2005
- Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004